Clinical Endpoints for Developing Pharamceuticals to Manage Patients with Sporadic or Genetic Risk of Colorectal Cancer | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
scientific articles

Clinical Endpoints for Developing Pharamceuticals to Manage Patients with Sporadic or Genetic Risk of Colorectal Cancer

key information

source: Expert review of gastroenterology & hepatology

year: 2012

authors: Rial N S, Zell J A, Cohen A M, Gerner E W

summary/abstract:

To reduce the morbidity and mortality from colorectal cancer (CRC), current clinical practice focuses on screening for early detection and polypectomy as a form of secondary prevention, complemented with surgical interventions when appropriate. No pharmaceutical agent is currently approved for use in clinical practice for the management of patients at risk for CRC. This article will review earlier attempts to develop pharmaceuticals for use in managing patients with a sporadic or genetic risk of CRC. It will also discuss therapeutic end points under evaluation in current efforts to develop drugs for treating CRC risk factors.

organisation: The University of Arizona Medical Center

abstract source full text source